In patients with type 2 diabetes and CKD with albuminuria, use of the glucagon-like peptide-1 (GLP-1) agonist semaglutide [40] and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone [41, 42] also reduces cardiovascular risk. Here, GCG is linked to chronic kidney disease.